Results 111 to 120 of about 1,300 (156)

Hypertrophic Obstructive Cardiomyopathy Present as Acute Myocardial Infarction in a Nonagenarian. [PDF]

JACC Case Rep
Wan X, Zhan Y, Gao Z, Sui Y, Ren J, Chen H, Chang Y, Zhang C, Wang Y.   +8 more
europepmc   +1 more source

Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Targeting Sarcomeric Hypercontractility with Demonstrated Long-Term Safety and Efficacy-A Narrative Review. [PDF]

J Clin Med
Mansour GK, Altebainawi AF, Hajjar AW, Sayed SBH, Alazem FA, Sajid MR.   +5 more
europepmc   +1 more source

Evolving strategies in obstructive hypertrophic cardiomyopathy: myosin inhibitors as monotherapy compared with beta-blockers. [PDF]

Heart Fail Rev
Grupper A, Sverdlov AL, Cheema BS, Nasrollahizadeh A, Hosseini K.   +4 more
europepmc   +1 more source

Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy: from Pathophysiology To Real World Data. [PDF]

Curr Cardiol Rep
Panichella G, Garofalo M, Ragagnin M, Fanizzi AI, Zampieri M, Del Franco A, Cappelli F, Pieroni M, Olivotto I.   +8 more
europepmc   +1 more source

Hemodynamic and symptomatic response in hypertrophic obstructive cardiomyopathy patients on myosin inhibitor therapy. [PDF]

Front Cardiovasc Med
Seuthe K, Feidakis A, Nies R, Brüwer M, Pennig L, Kaya K, Ten Freyhaus H, Baldus S, Pfister R.   +8 more
europepmc   +1 more source

ODYSSEY-HCM trial (mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy). [PDF]

Eur Heart J Cardiovasc Pharmacother
Monda E, Limongelli G.
europepmc   +1 more source

Mavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM. [PDF]

Circ Genom Precis Med
Bilen O, Adler A, Bastiaenen R, MacNamara JP, Paratz E, Maor E, Arad M, Gold M, Patel N, Pruett C, Burford E, Arora G, Maksabedian Hernandez EJ, Han X, Schuler P, Sandler B, Li L, Tian D, Arora P, COLLIGO-HCM investigators.   +19 more
europepmc   +1 more source

Mavacamten for symptomatic obstructive hypertrophic cardiomyopathy

openaire   +1 more source